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Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis and a need for better prognostica-
tion and novel treatments. The aim of this national cohort study was to investigate clinical outcome, prognostic factors, andro-
gen receptor (AR) and human epidermal growth factor receptor 2 (HER2) expression. SDC patients diagnosed between 1990
and 2014 were identified by the Nationwide Network and Registry of Histo- and Cytopathology in the Netherlands (PALGA).
Subsequently, medical records were evaluated and pathological diagnoses reviewed. Data were analyzed for overall survival
(OS), disease-free survival (DFS), distant metastasis-free survival (DMFS) and prognostic factors. AR was evaluated by immuno-
histochemistry (IHC), HER2 by IHC and fluorescent in-situ hybridization. A total of 177 patients were included. The median age
was 65 years, 75% were male. At diagnosis, 68% presented with lymph node metastases and 6% with distant metastases.
Median OS, DFS and DMFS were 51, 23 and 26 months, respectively. In patients presenting without distant metastases, the
absolute number of positive lymph nodes was associated with poor OS and DMFS in a multivariable analysis. AR and HER2
were positive in 161/168 (96%) and 44/153 (29%) tumors, respectively, and were not prognostic factors. SDC has a dismal
prognosis with primary lymph node involvement in the majority of patients. The absolute number of lymph node metastases
was found to be the only prognostic factor for DMFS and OS. AR expression and—to a lesser extent—HER2 expression hold
promise for systemic treatment in the metastatic and eventually adjuvant setting.
Key words: salivary duct carcinoma, salivary gland neoplasms, androgen receptors, receptor, ErbB-2, prognosis, survival, in situ hybridiza-
tion, ﬂuorescence, immunohistochemistry
This article was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, 2016.
Conflict of Interest: S.F. Oosting
Potential Financial Conflict: Research grant Pﬁzer, Research grant Novartis
DOI: 10.1002/ijc.31353
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or
adaptations are made.
History: Received 10 Sep 2017; Accepted 23 Jan 2018; Online 1 Mar 2018
Correspondence to: Prof. Dr Carla M. L. van Herpen, Department of Medical Oncology, Radboud University Medical Center, P.O. Box
9101, 6500 HB Nijmegen, The Netherlands, Tel.: 131-24-366-7251, E-mail: Carla.vanherpen@radboudumc.nl
C
an
ce
r
E
p
id
em
io
lo
g
y
Int. J. Cancer: 00, 00–00 (2018) VC 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
International Journal of Cancer
IJC
Salivary duct carcinoma (SDC) is a rare subtype of salivary
gland cancer (SGC). It was ﬁrst described in 1968,1 and
deﬁned as a distinctive entity in 1990.2 SDC usually affects
middle-aged men and the tumor is often located in the
parotid gland. Patients frequently present with locally
advanced disease. Primary treatment consists of resection of
the primary tumor and neck dissection, usually followed by
radiotherapy. SDC is characterized by a high rate of distant
metastases resulting in a limited overall survival (OS).3
Immunohistochemically, SDC resembles prostate cancer,
because of common expression of the androgen receptor
(AR).4 Androgen deprivation therapy (ADT) in a small series
showed a 50% clinical beneﬁt rate with a median duration of
12 months.5 Morphologically, SDC shows similarities with
invasive ductal carcinoma of the breast. However, SDC only
rarely shows estrogen and progesterone receptor expression.
Expression of the Human Epidermal Growth Factor
Receptor 2 (HER2) was reported in 44% of 32 patients with
SDCs.6
Due to the rarity of disease, only relatively small cohorts
have been described and prognostic factors remain to be eluci-
dated. The largest studies with 495 SDC patients based on the
National Cancer Database (NCDB) and with 228 SDC patients
based on the Surveillance, Epidemiology, and End Results Pro-
gram (SEER) database, lack vital information on the occurrence
of local and regional recurrences, distant metastases, the use of
systemic therapy and AR or HER2 expression.3 Furthermore,
no pathological review was performed in both studies.
Thanks to the unique collaboration between the Dutch
Pathology Network PALGA and the national network of
head and neck centers, we collected data of patients diag-
nosed with SDC in the Netherlands and aimed to evaluate
clinicopathological characteristics (such as AR and HER2
expression and primary treatment) in relation to clinical out-
come and prognostic factors.
Patients and Methods
Patient selection
Patients diagnosed with SDC between 1990 and 2014 were
identiﬁed by means of a retrospective search by the Nationwide
Network and Registry of Histo- and Cytopathology in the Neth-
erlands (PALGA).7 As all Dutch pathology laboratories partici-
pate in this network, all patients with a registered diagnosis of
SDC in the Netherlands were enrolled. All patients were coded
by PALGA and clinical data could be correlated with the patho-
logical features in a coded procedure.
Clinical data
Clinical data were collected from the medical records and
were obtained with permission of treating physicians according
to Dutch national laws and Good Clinical Practice. Review by
a medical ethical committee was not obligatory by Dutch law
due to the retrospective nature of the observations.
Pathology
For all patients, hematoxylin and eosin (H&E) stained slides,
formalin-ﬁxed parafﬁn-embedded (FFPE) tumor blocks and
corresponding anonymous pathological reports were
requested. All patient materials used in this study were
obtained during routine patient care, and used for scientiﬁc
research with permission by Dutch Law (“Code for Second-
ary Use of Human Tissue,” Dutch Federation of Medical Sci-
entiﬁc Societies). H&E slides were used for re-evaluation of
the diagnosis and to mark areas of primary tumor by an
experienced pathologist (UF). From each “donor” block, one
to three cores of primary tumor were transferred into the
“recipient” tissue micro array (TMA) block, using the TMA
Grandmaster by Sysmex. From the new TMA “recipient
blocks,” slides were produced for further analysis. Each TMA
slide was analyzed for AR and HER2 and scored by the
pathologist (UF), who was blinded for the clinical outcome.
AR (immunohistochemistry (IHC)) and HER2 (either IHC
or ﬂuorescent in-situ hybridization (FISH)) acquired during
routine clinical care procedures was permitted in case it was
not possible to determine AR or HER2 with a TMA. In case
of heterogeneity between cores or between TMA and clini-
cally obtained results, the highest score was used.
For AR expression, the AR polyclonal antibody of Santa
Cruz was used, dilution 1:200, pretreatment with citrate (pH
6.0) for 10 min in a pretreatment module (Labvision/thermo
scientiﬁc by Klinipath/VWR). Then, immunostaining was
carried out with the detection system (Brightvision) of
Immunologic, Duiven, the Netherlands. AR immunhisto-
chemistry was executed in the Radboudumc. AR was scored
positive or negative based on diffuse nuclear staining, as
described in the WHO classiﬁcation of SDC.8
HER2 was determined upfront by both IHC and FISH.
The Hercepkit of DAKO was used according to protocol for
What’s new?
Salivary duct carcinoma (SDC) is a rare and often fatal malignancy. Little is known about associations between its pathological
features and clinical outcome. In this study, clinicopathological factors were analyzed for 177 patients diagnosed with SDC in
The Netherlands between 1990 and 2014. The data show that median overall survival (OS) and distant metastasis-free sur-
vival (DMFS) were 51 and 26 months, respectively. At diagnosis, 68% of patients presented with lymph node metastases.
Lymph node positivity was associated with poor OS and poor DMFS. The absolute number of metastatic lymph nodes was the
only significant prognostic factor for survival in a multivariate analysis. Androgen receptor and human epidermal growth factor
2 (HER2) were positive in 96% and 29%, respectively and were not a prognostic factor.
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HER2 immunostaining. For HER2 FISH, the probe of Krea-
tech (location of hybridization on 17q12cep17) was used. The
probe was incubated according to standard ISH protocol.
Scoring of HER2 was performed according to guidelines
from the American Society of Clinical Oncology (ASCO) and
College of American Pathologists (CAP) analogous to breast
cancer.9 HER2 IHC and FISH were scored independently.
After scoring IHC and FISH, the results were compared. As
the guideline does not mention how to report on discrepan-
cies between IHC and FISH, we considered the result of
HER2 FISH directive in discordant cases, that is, HER2
IHC31 and HER2 FISH negative was scored as HER2
negative.
Definitions and statistical analysis
Lymph node ratio (LNR) was deﬁned as the number of
tumor-positive lymph nodes divided by the total number of
lymph nodes resected. Date of diagnosis was deﬁned as date
of obtaining the ﬁrst histological proof of SDC. In case the
diagnosis was conﬁrmed in a later stadium, the original date
of obtaining the histopathological material was used. Overall
survival (OS) was measured from date of diagnosis until
death of any cause. Patients alive at last known follow-up
date were censored. Disease-free survival (DFS) was mea-
sured from date of surgery until date of local or regional
recurrence, distant metastases or death of any cause, which-
ever came ﬁrst. Patients alive without disease at last known
follow-up were censored. Distant metastasis free survival
(DMFS) was deﬁned as date of diagnosis until date of distant
metastases or death of any cause, whatever came ﬁrst.
Patients alive without distant metastasis were censored. Sur-
vival curves were estimated with the Kaplan–Meier method.
To investigate association between patient and tumor charac-
teristics and survival, univariate Cox proportional hazards
regression models were ﬁtted ﬁrst. Next, a multivariable Cox
regression model was estimated with a forward selection pro-
cedure based on the Wald test at signiﬁcance level of 0.05.
The variables used in the multivariable analysis for OS and
DMFS included gender, age (categorical), T- and N-stage,
number of positive lymph nodes (categorical), AR, HER2,
carcinoma ex pleomorphic adenoma, primary tumor site and
resection margins. Patients with metastatic disease at diagno-
sis and patients with missing values in one or more of the
variables were excluded from the multivariable analysis. Data
were analyzed using SPSS version 22.0.
Results
Patient and tumor characteristics
Pathological review led to the inclusion of 177 eligible SDC
patients out of 294 patients in the PALGA database (Fig. 1).
Patient characteristics are shown in Table 1. The median age
was 65 years [range 38–92], and the majority was male
(75%). The parotid gland was the most affected (82%) sali-
vary gland. Thirty-six percent of patients had an SDC arising
from a pleomorphic adenoma (carcinoma ex pleomorphic
adenoma). One-hundred and twenty patients (68%) had
lymph node metastases. Eleven patients (6%) presented with
distant metastases. Ninety-six percent of 168 evaluable
tumors were AR positive. Twenty-nine percent of the 153
evaluable tumors were HER2 positive. One-hundred and
forty patients were evaluated for AR and HER2 using the
TMA, the scores of the remaining patients were based on
routine clinical evaluations. Table 2 shows the number of
patients evaluated by FISH and IHC. Four patients had
HER2 IHC31 but had a negative HER2 FISH, and were
scored as HER-2 negative.
Primary treatment with curative intent
Of the 177 patients, 162 patients underwent primary surgery
with curative intent.
Fourteen patients did not have surgery because of an irre-
sectable tumor in 3 patients or distant metastases at diagnosis
in 11 patients. One patient underwent primary surgery of the
primary tumor and neck dissection, but in retrospect had dis-
tant metastases on baseline imaging, and was not considered
as having been treated with curative intent.
Figure 1. Consort diagram of inclusion of SDC patients. PALGA is
the Nationwide Network and Registry of Histo- and Cytopathology
in the Netherlands.
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Surgery. One hundred and sixty-two patients had primary
surgery, of which 123 patients had a resection of the primary
tumor and neck dissection, 36 patients only had a resection
of the primary tumor. Three patients only underwent a neck
dissection, because no primary tumor could be detected. In
patients who underwent a neck dissection (n5 126), the
median number of tumor positive lymph nodes was 4 [range
0–97] (Table 1). Figure 2 shows the number of tumor posi-
tive lymph nodes plotted against the total number of lymph
nodes examined in the resected specimens (number of
patients5 126). The median LNR was 0.20.
Radiotherapy. One hundred and forty-nine of 162 patients
(91%) received postoperative radiotherapy. The median dose
was 66 Gy (range 14–70 Gy). Only one of these patients
underwent adjuvant concurrent chemoradiotherapy (CRT)
(radiotherapy combined with weekly Cisplatin).
Patterns of recurrences and distant metastases
Eighty-seven out of 162 patients (54%) developed locore-
gional recurrence and/or distant metastases after primary
treatment with curative intent. Figure 3a shows the Venn
Table 1. Patient’s and tumor characteristics
Characteristics
Number of
patients (n5 177)
Median age, in years 65
Range, in years 38–92
Age, in years, n (%)
50 19 (11)
51–60 43 (24)
61–70 54 (31)
71–80 41 (23)
>80 20 (11)
Gender, n (%)
Male 133 (75)
Female 44 (25)
Primary tumor, n (%)
Parotid gland 145 (82)
Submandibular gland 19 (11)
Sublingual gland 2 (1)
Other
Minor salivary glands 7 (4)
Lacrimal gland1 1 (1)
Unknown 3 (2)
Presenting symptoms, n (%)
Painless mass 84 (48)
Painful mass 27 (15)
Facial nerve paralysis 51 (29)
Unknown 15 (9)
Carcinoma ex pleomorphic
adenoma, n (%)
Yes 63 (36)
No (“de novo”) 114 (64)
TNM stadium
T1/T2/T3/T4/Tx 29/49/20/68/11
(%) (16/28/11/38/6)
N0/N1/N2/N3 57/15/104/1
(%) (32/8/59/1)
M0/M1 166/11
(%) (94/6)
Overall stage
I/II/III/IV/unknown 16/18/10/130/3
(%) (9/10/5/73/2)
Primary treatment with curative
intent2 (n5162)
Surgery, n (%)
Resection primary tumor with
neck dissection
123 (76)
Resection primary tumor
without neck dissection
36 (22)
Neck dissection only 3 (2)
Table 1. Patient’s and tumor characteristics (Continued)
Characteristics
Number of
patients (n5 177)
Postoperative radiotherapy, n (%)
Yes 149 (91)
No 13 (9)
Neck dissection3
Median number of resected
lymph nodes, range
27 (1–122)
Median number of positive lymph
nodes, range
4 (0–97)
Median lymph node ratio, range 0.20 [0–1.00]
Androgen receptor (AR), n (%)4
Positive 162 (96)
Negative 6 (4)
HER2, n (%)5
Positive 45 (29)
Negative 108 (71)
HER2 determination methods, n
(%)
FISH and IHC 140 (92)
FISH 5 (3)
IHC 8 (5)
1Histopathological appearance of SDC despite its localization in the
lacrimal gland.
2One patient underwent primary surgery despite distant metastases on
baseline imaging in retrospect.
3n5126 patients.
4Nine patients had no AR result. n5168 patients.
5Twenty-four patients had no HER2 result. n5 153 patients.
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Table 2. Univariate and multivariable analyses for overall survival and distant metastasis free survival
Univariate
OS DMFS
Factor No of patients HR1 95% CI p HR1 95% CI p
Increasing age in years 177 1.02 [1.00–1.03] 0.09 1.00 [0.99–1.02] 0.58
Age, categories1,2 0.31 0.67
50 years 19 1.00 1.00
51–60 years 43 2.46 [1.01–6.00] 0.048 1.66 [0.83–3.30] 0.15
61–70 years 54 2.02 [0.83–4.95] 0.12 1.48 [0.74–2.93] 0.27
71–80 years 41 1.98 [0.79–4.98] 0.15 1.40 [0.69–2.83] 0.35
>80 years 20 2.74 [1.01–7.42] 0.048 1.24 [0.54–2.86] 0.62
Gender1,2
Female 44 1.00 1.00
Male 133 2.24 [1.24–4.06] 0.008 2.10 [1.27–3.49] 0.004
Carcinoma ex pleomorphic adenoma1,2
No (“de novo”) 114 1.00 1.00
Yes 63 0.80 [0.50–1.26] 0.33 0.88 [0.59–1.29] 0.50
T-stadium1,2 0.18 0.008
T1/T2 77 1.00 1.00
T3/T4 89 1.50 [0.95–2.36] 0.08 1.88 [1.26–2.79] 0.002
Tx 11 1.56 [0.68–3.54] 0.29 1.65 [0.77–3.55] 0.20
N-stadium1,2
N0 57 1.00 1.00
N1/N2/N3 120 2.28 [1.36–3.81] 0.002 2.24 [1.44–3.49] 0.000
Number of positive lymph nodes1,2 159 0.000 0.000
0 56 1.00 1.00
1–2 27 1.13 [0.54–2.40] 0.74 1.15 [0.60–2.23] 0.67
3–15 45 2.03 [1.11–3.72] 0.022 2.03 [1.20–3.45] 0.009
>15 31 3.83 [1.98–7.43] 0.000 4.38 [2.47–7.78] 0.000
Lymph node ratio (LNR)
<0.20 64 1.00 1.00
>0.20 60 2.43 [1.42–4.16] 0.001 2.36 [1.48–3.78] 0.000
M-stadium3
M0 166 1.00
M1 11 4.26 [2.08–8.71] 0.000
Resection margins1,2 0.31 0.57
Free 16 1.00 1.00
Close 15 0.58 [0.17–1.92] 0.37 1.08 [0.44–2.66] 0.87
Tumor-positive margins 127 1.23 [0.59–2.59] 0.58 1.36 [0.70–2.64] 0.37
Primary tumor site1,2 0.90 0.96
Parotid gland 145 1.00 1.00
Submandibular gland 19 0.85 [0.43–1.72] 0.66 0.93 [0.51–1.71] 0.82
Other 10 1.03 [0.44–2.39] 0.95 0.93 [0.43–2.02] 0.86
Androgenreceptor1,2
Negative 6 1.00 1.00
Positive 162 1.69 [0.53–5.39] 0.38 1.41 [0.52–3.86] 0.50
HER21,2
Negative 108 1.00 1.00
Positive 45 1.08 [0.65–1.81] 0.76 1.23 [0.80–1.89] 0.35
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diagram of local, regional and distant recurrences in 162
patients treated with curative intent. Eighty-four out of 177
patients (47%) had distant metastases during the course of
disease; 11 (6%) patients had distant metastatic disease at
diagnosis and 73/162 (45%) patients developed distant metas-
tases after primary treatment with curative intent. Figure 3b
shows the sites of distant metastases for 84 patients who had
distant metastases at diagnosis (n5 11) or developed distant
metastases after treatment with curative intent (n5 73). Pul-
monary (54%), bone (46%) and lymph nodes (42%) metasta-
ses were most frequently encountered. Brain metastases
occurred in 15 (18%) patients. Of these 15 patients with
brain metastases, the HER2 status was available in 13. Five
out of 13 patients (38%) were HER2 positive, and the other
8 patients (62%) were HER2 negative. The median time until
the occurrence of distant metastases was 16 months (range
1–69 months).
Treatment with palliative intent. In total, 84 patients had
distant metastases (11 at time of diagnosis and 73 after
treatment with curative intent) and three patients had unre-
sectable disease. One of these three patients received primary
radiotherapy. The other two patients were treated with pallia-
tive ADT. Thirty-six patients with distant metastatic SDC
received ADT as ﬁrst- or second-line palliative treatment. Fif-
teen (18%) patients underwent chemotherapy and four (5%)
patients targeted therapy. Most regimens included either tax-
anes (docetaxel or paclitaxel) or platinum (cisplatin or carbo-
platin) based chemotherapy. Some patients received multiple
lines of systemic therapy. Forty-four (54%) of 84 patients
with distant metastases received only best supportive care. A
total of 39 (46%) patients with distant metastases underwent
radiotherapy with palliative intent.
Survival
After a median follow-up of 26 months, 84 of 177 patients
had died. The 5- and 10-years survival were estimated as
43% [95% CI 33–52%] and 26% [95%CI 15–37%], respec-
tively. The 5- and 10-year DFS were estimated as 28% [95%
CI 20–36%] and 17% [95% CI 8–25%], respectively. The 5-
and 10-year DMFS were 32% [95% CI 24–40%] and 20%
[95% CI 2–29%], respectively.
Estimates for the median OS, DFS and DMFS were 51
months (95% CI 40–61 months), 23 months (95% CI 18–27
months) and 26 months (95% CI 20–34 months), respec-
tively. The Kaplan–Meier curves for OS, DFS and DMFS are
shown in Figures 4a–4c.
Prognostic factors
Patient selection. All 177 patients were included in the uni-
variate analysis. Patients with distant metastases at diagnosis
were not included in multivariable analyses for OS and
DMFS. Owing to missing values, only 136 patients were
included in the multivariable predictive model for OS and
DMFS.
Overall survival. Univariate analysis showed that male gen-
der, high N-stadium, increasing number of tumor positive
lymph nodes, LNR and primarily metastatic disease at diag-
nosis were associated with poor OS. The multivariable
Multivariable3
OS DMFS
Factor No of patients HR1 95% CI p HR1 95% CI p
Number of positive
lymph nodes
136 0.003 0.000
0 49 1.00 1.00
1–2 22 1.20 [0.50–2.86] 0.69 1.26 [0.60–2.66] 0.54
3–15 41 2.17 [1.09–4.32] 0.028 2.25 [1.25–4.06] 0.007
>15 25 3.96 [1.84–8.55] 0.000 4.73 [2.48–9.00] 0.000
Abbreviations: 95%CI, 95% confidence interval; DMFS, distant metastasis free survival; HR, hazard ratio; OS5 overall survival.
1Variables included in multivariable analyses for OS.
2Variables included in multivariable analyses for DMFS.
3Patients who presented with primarily metastatic disease were not included in the multivariable analysis.
Figure 2. Tumor-positive lymph nodes are plotted against the total
number of lymph nodes during neck dissection (number of patient-
s5126). The dark blue line represents the line at which all
resected lymph nodes would have been tumor positive. [Color fig-
ure can be viewed at wileyonlinelibrary.com]
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prediction model only contained the number of positive
lymph nodes as independent variable: an increasing number
of positive lymph nodes negatively affects survival (overall
p5 0.003) (3–15 lymph nodes vs. 0 lymph nodes HR 2.17,
95% CI 1.09–4.32, p5 0.028; >15 lymph nodes vs. 0 lymph
nodes HR 3.96, 95% CI 1.84–8.55, p5 0.000). The number of
lymph nodes was categorized due to a nonlinear correlation
with OS.
No signiﬁcant association was found between AR and
HER2 and OS in the univariate as well as the multivariable
analysis. The results of the univariate and multivariable anal-
yses for OS are shown in Table 2.
Distant metastasis free survival. Male gender, high T-
stadium, high N-stadium, increasing numbers of positive
lymph nodes and LNR were associated with poor DMFS
using univariate analysis. The ﬁnal multivariable prediction
model only contained the number of positive lymph nodes as
independent variable; an increasing number of positive
lymph nodes is a prognostic factor for poor DMFS (overall
p5 0.000) (3–15 lymph nodes vs. 0 lymph nodes HR 2.25,
95% CI 1.25–4.06, p5 0.007; >15 lymph nodes vs. 0 lymph
nodes HR 4.73, 95% CI 2.48–9.00, p5 0.000). The number of
lymph nodes was categorized due to nonlinear correlation
with DMFS. From the univariate and multivariable analysis,
no signiﬁcant association was found between DMFS and AR
and HER2. The results of the univariate and multivariable
analysis for DMFS are displayed in Table 2.
Discussion
In this article, we present 177 patients with SDC, which rep-
resents the largest series of SDC patients with pathological
review worldwide. These data provide extensive insight in
treatment, clinical outcome, AR and HER2 expression/ampli-
ﬁcation and prognostic factors in SDC patients. This study
underscores the aggressive clinical course characterized by a
high rate of distant metastases (47%), and a median OS of 51
months. AR and HER2 were positive in 96 and 29% respec-
tively; both were of no prognostic value as they were not sig-
niﬁcantly associated with OS and DMFS. The number of
positive lymph nodes was the only factor independently asso-
ciated with poor OS and DMFS.
SDC has a high propensity for lymph node and distant
metastases; 68% of our patients presented with lymph node
metastases, which is higher than the 46.6% and 49% reported
by Osborn and Jayaprakesh et al.3,10 An abundancy of tumor
positive lymph nodes was observed in neck dissections. Fur-
thermore, distant metastases were observed relatively short
after primary diagnosis with a median time until distant
metastases of only 16 months. Although distant metastases
occurred mostly in the lungs, bones and lymph nodes, a wide
variety of metastatic sites were seen, of which the 18% rate of
brain metastasis was most notable. Local and regional recur-
rences were often accompanied by distant metastases. In this
study, 67% of patients with a local or regional recurrence
also had distant metastases, as shown in Figure 3a, which
corresponds to the 23–75% found in two other reports.11,12
Therefore, in case of local or regional recurrences, we sug-
gest thorough screening for distant metastases, as this may
change treatment from curative to palliative intent. More-
over, despite locoregional control, distant metastases were
encountered during follow-up in 42 patients. Notably, 54%
of patients with metastatic disease did not receive any
form of systemic treatment. Possible explanations for this
may be the extensiveness of disease, performance status,
co-morbidity and unfamiliarity of physician with the treat-
ment of this rare tumor type, especially during the early
years of the time period that we have studied. This may
have inﬂuenced the overall survival of SDC patients in
general.
Figure 3. Patterns of disease recurrence. (a) Breakdown of local
and regional recurrences and distant metastases in 87 patients
with a recurrence. The numbers in the circles represent the abso-
lute number of patients with local and regional recurrences and
the presence of distant metastases. Patients with primarily meta-
static disease are not included in this figure. (b) Localization of
distant metastases sorted by percentage of presence in 84
patients with distant metastases. Patients with primarily metastatic
disease were included in this figure. [Color figure can be viewed at
wileyonlinelibrary.com]
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Recently, a few cohort studies on patients with SDC were
published. The cohort based on the National Cancer Data-
base (NCDB) is the largest cohort of SDC patients with 495
patients (no median OS described for all patients) followed
by the SEER database with 228 patients (median OS 79
months).3,10 However, lack of pathology review has a risk of
including patients with other diagnosis as the histological
diagnosis of SDC is notoriously difﬁcult. The median OS in
this study (51 months) was comparable to a cohort study of
56 patients in a single institution in Korea (OS of 48
months).13 In a Japanese study with 141 SDC patients, where
all tumors were pathologically reviewed, three-year OS was
73% versus 57% in our series.11
In our series, 96% of tested tumors had a positive AR.
This is comparable with other series of SDC patients report-
ing AR positivity up to 89%.4 AR positivity, in the presence
of typical morphological features, is strongly suggestive for
SDC, although other subtypes of SGC may express AR.14
ADT is an interesting therapeutic option for AR-positive
SDC.5 The results of ﬁrst-line ADT in our patients will be
published in a separate article.15
We conﬁrmed the presence of HER2 in 29% of tested
cases, which is in line with the previously described HER2
ampliﬁcation/expression in 27% (of 41), 32% (of 31) and
44% (of 32) SDC cases.6,16,17 We reported on four patients
with HER2 IHC31 with HER2 FISH-negative tumor sam-
ples. Although this is unusual, it is known from comparative
studies that this may occur.18 Recently, preliminary data for
45 patients with HER2-positive advanced unresectable SGC
(of the ductal subtype) treated with docetaxel and trastuzu-
mab in a phase 2 trial showed promising results, that is,
overall response rate of 69%, median PFS of 11.3 months
and median OS of 38.0 months.19 These results seem to sup-
port treating HER2-positive SDC patients with trastuzumab
plus docetaxel.
Unfortunately, it was not possible to correlate clinical out-
comes to other genetic alterations such as TP53 and PI3KCA.
Future research may include characterization of genetic alter-
ations and clinical outcomes of SDC patients.
Studies demonstrated a correlation between lymph node
metastases and OS. There seems to be no consensus on the
best way of categorizing lymph node metastases, whereby
classiﬁcations comparing N0–1 versus N2–3, N2b-c versus
N0-N2a or N0 versus any N1 disease are used.3,12,13,20 We
demonstrated in the univariate analysis that lymph node
metastases is indeed a signiﬁcant prognostic factor. However,
in the multivariable analysis, the absolute number of tumor
positive lymph nodes is a stronger prognostic factor than the
N-stage and LNR.21 We therefore suggest a categorizing sys-
tem according to the absolute number of tumor positive
lymph nodes (categorized as 0, 1–2, 3–15 and >15 lymph
nodes), although this needs to be validated in other SDC
cohorts.
One may argue if the patient with SDC of the lacrimal
gland should be included in the analysis; however, the histo-
pathological features in this particular patient included
comedo-type necrosis and AR positivity. Recently, another
case of AR-positive SDC of the lacrimal gland was described
in literature.22
Figure 4. Kaplan–Meier curves for overall survival (OS), disease-
free survival (DFS) and distant metastasis free survival (DMFS)
based on data of 177 SDC patients. (a) Kaplan–Meier curve for OS
based on data of 177 SDC patients. Estimated median OS was 51
months (95% CI 40–61 months). (b) Kaplan–Meier curves for DFS
based on data of 177 SDC patients. Estimated median DFS was 23
months (95% CI 18–27 months). (c) Kaplan–Meier curve of DMFS
based on data of 177 SDC patients. Estimated median DMFS was
26 months (95% CI 20–34 months). [Color figure can be viewed at
wileyonlinelibrary.com]
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The main strengths of this study are the large number of
patients data collected using a nationwide search strategy by
PALGA, which covers 95–100% of all cancer patients, and
especially the pathological review of SDC cases. A major
advantage of our data, as compared to the larger, national
NCDB and SEER databases, is the availability of individual
patient data in our cohort. Extensive data on diagnosis, treat-
ment, recurrence patterns and survival could be collected and
has given valuable insights not only in the presentation but
also in the course of the disease. We were therefore able to
analyze meaningful prognostic factors in univariate and mul-
tivariable analyses. Limitations of this study are mainly due
to its’ retrospective nature, the absence of FFPE blocks for
AR and HER2 testing in some cases, and a not 100% cover-
age of all detailed information. Only tumors classiﬁed as
SDC were included; therefore, patients that may have been
wrongfully classiﬁed, that is, as another subcategory of the
SGCs, may have been missed.
In conclusion, we presented 177 SDC patients with patho-
logical review of the diagnosis. The median OS was just over
4 years, and the disease was characterized by a high initial
lymph node involvement and development of a high rate of
distant metastases. In the multivariable analysis, the absolute
number of positive lymph nodes was the only signiﬁcant
prognostic factor for both poor OS and DMFS. We advocate
the determination of AR and HER2 as this may have thera-
peutic consequences, although these are not prognostic fac-
tors. Given the high recurrence rate, future clinical research
could encompass adjuvant treatment in high-risk lymph
node-positive patients.
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